Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Treasury Shares (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Treasury Shares for 4 consecutive years, with $42.3 million as the latest value for Q4 2013.

  • Quarterly Treasury Shares changed 0.0% to $42.3 million in Q4 2013 from the year-ago period, while the trailing twelve-month figure was $42.3 million through Dec 2013, changed 0.0% year-over-year, with the annual reading at $42.3 million for FY2013, 0.0% changed from the prior year.
  • Treasury Shares hit $455547.0 in Q4 2025 for Ligand Pharmaceuticals, down from $459213.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $512361.0 in Q2 2024 to a low of $162152.0 in Q1 2022.
  • Historically, Treasury Shares has averaged $376518.1 across 5 years, with a median of $374757.5 in 2023.
  • Biggest five-year swings in Treasury Shares: grew 0.13% in 2011 and later changed 0.0% in 2012.
  • Year by year, Treasury Shares stood at $42.2 million in 2010, then rose by 0.13% to $42.3 million in 2011, then changed by 0.0% to $42.3 million in 2012, then changed by 0.0% to $42.3 million in 2013.
  • Business Quant data shows Treasury Shares for LGNDZ at $42.3 million in Q4 2013, $42.3 million in Q3 2013, and $42.3 million in Q2 2013.